NOT FOR DISTRIBUTION
Header cover image

Market Cap

AU$139.3m

Last Updated

2021/05/07 08:29 UTC

Data Sources

Company Financials +

Executive Summary

MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. More Details


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has MGC Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MXC is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 25% a week.

Volatility Over Time: MXC's weekly volatility has increased from 16% to 25% over the past year.


Market Performance


7 Day Return

1.7%

MXC

-1.2%

AU Pharmaceuticals

0.3%

AU Market


1 Year Return

134.6%

MXC

5.6%

AU Pharmaceuticals

35.9%

AU Market

Return vs Industry: MXC exceeded the Australian Pharmaceuticals industry which returned 1.8% over the past year.

Return vs Market: MXC exceeded the Australian Market which returned 37.3% over the past year.


Shareholder returns

MXCIndustryMarket
7 Day1.7%-1.2%0.3%
30 Day-10.3%-6.1%1.8%
90 Day79.4%-8.3%2.8%
1 Year134.6%134.6%5.8%5.6%39.9%35.9%
3 Year-17.6%-17.6%-41.6%-42.1%30.1%14.7%
5 Year35.6%35.6%-31.4%-34.7%60.1%29.9%

Long-Term Price Volatility Vs. Market

How volatile is MGC Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MGC Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

104.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MXC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MXC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MXC is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.

PE vs Market: MXC is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MXC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MXC is overvalued based on its PB Ratio (104.1x) compared to the AU Pharmaceuticals industry average (3.3x).


Future Growth

How is MGC Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

68.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MGC Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has MGC Pharmaceuticals performed over the past 5 years?

-22.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MXC is currently unprofitable.

Growing Profit Margin: MXC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MXC is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.

Accelerating Growth: Unable to compare MXC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MXC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).


Return on Equity

High ROE: MXC has a negative Return on Equity (-1239.43%), as it is currently unprofitable.


Financial Health

How is MGC Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: MXC's short term assets (A$4.1M) do not cover its short term liabilities (A$7.4M).

Long Term Liabilities: MXC's short term assets (A$4.1M) exceed its long term liabilities (A$3.2M).


Debt to Equity History and Analysis

Debt Level: MXC's debt to equity ratio (7%) is considered satisfactory.

Reducing Debt: MXC's debt to equity ratio has reduced from 15.3% to 7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MXC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MXC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32% each year


Dividend

What is MGC Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MXC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MXC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MXC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MXC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MXC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Roby Zomer

5.25yrs

Tenure

AU$439,986

Compensation

Mr. Roby Reuven Zomer is a Co-Founder of MGC Pharmaceuticals Limited. Mr. Zomer has been Managing Director since May 2018 and Chief Executive Officer of MGC Pharmaceuticals Limited (Australia) since Februa...


CEO Compensation Analysis

Compensation vs Market: Roby's total compensation ($USD342.03K) is about average for companies of similar size in the Australian market ($USD287.37K).

Compensation vs Earnings: Roby's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MXC's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: MXC's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MXC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.9%.


Top Shareholders

Company Information

MGC Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MGC Pharmaceuticals Limited
  • Ticker: MXC
  • Exchange: ASX
  • Founded: 2014
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$139.278m
  • Shares outstanding: 2.28b
  • Website: https://www.mgcpharma.com.au

Location

  • MGC Pharmaceuticals Limited
  • 1202 Hay Street
  • West Perth
  • Western Australia
  • 6005
  • Australia

Listings


Biography

MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for th...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/07 08:29
End of Day Share Price2021/05/05 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.